Equity Profile

DNTH

Dianthus Therapeutics, Inc.

Health CareBiotechnology$6.1B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

$-1.02

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNTH Q2-2026 Earnings Preview

Context

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, its work is crucial as it aims to address unmet medical needs and improve patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

In Q1-2026, Dianthus reported an EPS of $-0.85, which was better than the expected $-1.17, resulting in a positive surprise. The stock reacted positively, gaining 1.01% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Dianthus to report a loss of $-1.02 per share this quarter, with no revenue anticipated. The market is watching closely for any signs of progress in product development.

Bull Case

If Dianthus can exceed EPS expectations and show any revenue, it could signal strong demand for its therapies, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to improve its EPS or continues to report no revenue, it could raise concerns about its financial health and future viability.

Key Metrics to Watch

EPS

$-1.02

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Dianthus be able to reduce its EPS loss from the consensus estimate of $-1.02?

A smaller loss could indicate improved cost management and operational efficiency, which would be viewed positively by investors.

Is there any revenue reported, even if minimal?

Any revenue would be a positive sign of market acceptance and demand for Dianthus's products, which is critical for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Dianthus to surprise on the upside, especially if they can show any revenue this quarter.

Supporting Evidence

The last quarter showed a significant EPS surprise, indicating potential for continued improvement.

Options pricing suggests a larger move than historical averages, indicating expectations of volatility.

The company's focus on innovative therapies could lead to unexpected revenue streams.

Key Risk

If Dianthus reports any revenue, it could challenge the consensus view of continued losses.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dianthus can show signs of financial improvement or if it will continue to struggle.

Bull Confirmed If

Reporting an EPS loss of less than $-1.02 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-1.02 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.01%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±23.0% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

38.6%

Calls (5K)P/C Ratio: 0.19Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats EPS expectations and reports any revenue, history suggests the stock could rise by around 4.47% on average after a miss.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

Should the company miss expectations, history suggests a potential decline of around 4.47%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product development timelines and potential market launches.
2Details on cost management strategies and operational efficiency improvements.
3Insights into market demand for their therapies and any customer feedback.
4Discussion on partnerships or collaborations that could enhance revenue potential.
5Management's outlook on future quarters and any guidance provided.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

$-1.02

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNTH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

In Q1-2026, Dianthus reported an EPS of $-0.85, which was better than the expected $-1.17, resulting in a positive surprise. The stock reacted positively, gaining 1.01% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Dianthus to report a loss of $-1.02 per share this quarter, with no revenue anticipated. The market is watching closely for any signs of progress in product development.

Bull Case

If Dianthus can exceed EPS expectations and show any revenue, it could signal strong demand for its therapies, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to improve its EPS or continues to report no revenue, it could raise concerns about its financial health and future viability.

Key Metrics to Watch

EPS

$-1.02

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Dianthus be able to reduce its EPS loss from the consensus estimate of $-1.02?

A smaller loss could indicate improved cost management and operational efficiency, which would be viewed positively by investors.

Is there any revenue reported, even if minimal?

Any revenue would be a positive sign of market acceptance and demand for Dianthus's products, which is critical for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Dianthus to surprise on the upside, especially if they can show any revenue this quarter.

Supporting Evidence

The last quarter showed a significant EPS surprise, indicating potential for continued improvement.

Options pricing suggests a larger move than historical averages, indicating expectations of volatility.

The company's focus on innovative therapies could lead to unexpected revenue streams.

Key Risk

If Dianthus reports any revenue, it could challenge the consensus view of continued losses.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dianthus can show signs of financial improvement or if it will continue to struggle.

Bull Confirmed If

Reporting an EPS loss of less than $-1.02 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-1.02 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.01%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±23.0% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

38.6%

Calls (5K)P/C Ratio: 0.19Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats EPS expectations and reports any revenue, history suggests the stock could rise by around 4.47% on average after a miss.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

Should the company miss expectations, history suggests a potential decline of around 4.47%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product development timelines and potential market launches.
2Details on cost management strategies and operational efficiency improvements.
3Insights into market demand for their therapies and any customer feedback.
4Discussion on partnerships or collaborations that could enhance revenue potential.
5Management's outlook on future quarters and any guidance provided.